Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism

A man smiling in a research lab.
September 7, 2021
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Maniruzzaman Lab Earns Grant to Research 3D Printed COVID-19 Treatment

A man holding up a dish in a lab.
May 26, 2021
The UT College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab earned a Texas Global Faculty Research Seed Grant for its work on patient-specific treatment of COVID-19.

Suh and PharmE3D Labs Win Fellowships for 3D Bioprinting Research

A woman smiling in front of a sign that says "Pharmacy."
March 18, 2021
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.

Mukhopadhyay Wins Research Excellence Award

A man standing in a research laboratory.
September 10, 2020
Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.

UT 3D Printing Labs Enter Patent License Agreement to Develop Digital 3D Drug Manufacturing and Advanced Drug Delivery Systems

Patient-centric 3D printing paradigm of medicines at the point-of-care.
July 17, 2020
Assistant Professor Mo Maniruzzaman’s Pharmaceutical Engineering and 3D Printing (PharmE3D) labs have entered an agreement with UK-based CoM3D to develop digital 3D drug manufacturing and advanced drug delivery systems.

Maniruzzaman Lab Collaboration Works to Develop Patient-Focused Medicines More Efficiently

mo lab 3d printer
April 27, 2020
To meet the need to develop methods to make drugs more soluble and usable, the Maniruzzaman Lab teamed up with Advanced Material Development (AMD) to address challenges with the reduction in quantity of new drugs coming to market.